A fully human antibody, single-chain antibody, and antigen-binding fragment targeting the BAFF-R antigen.

By using a fully human phage antibody library screening technology, high-affinity and highly specific targeted BAFF-R antibodies were obtained, solving the problems of high immunogenicity and insufficient affinity in existing technologies, and achieving effective treatment of BAFF-R-related diseases.

CN116041515BActive Publication Date: 2026-11-10NANJING IASO BIOTHERAPEUTICS CO LTD +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202211146308.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-09-20
Publication Date
2026-11-10
Estimated Expiration
2042-09-20

AI Technical Summary

Technical Problem

Existing BAFF-R-targeting antibodies have problems such as high immunogenicity and insufficient affinity in clinical applications, and lack highly efficient BAFF-R-specific binding agents.

Method used

Using a fully human phage antibody library screening technology, fully human monoclonal antibodies targeting BAFF-R were directly obtained. High-affinity and specific antibody clones were screened using phage display technology. The amino acid sequences are: LCDR1: SSDVGGYNY, LCDR2: EVS, LCDR3: SSYTSSSTYV, HCDR1: GFSLSTSGVG, HCDR2: IYWDDDK, HCDR3: ARYAGQYSGMWPWDY.

Benefits of technology

The obtained fully human antibody specifically binds to BAFF-R positive cell lines, exhibiting low immunogenicity and high affinity (KD value of 7.62E-10), making it suitable for the development of antibody drugs and cell therapy drugs, and also applicable to the treatment of BAFF-R related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116041515B_ABST
    Figure CN116041515B_ABST
Patent Text Reader

Abstract

This invention provides a fully human antibody, single-chain antibody, and antigen-binding fragment targeting the BAFF-R antigen. The fully human antibody, single-chain antibody, and antigen-binding fragment targeting the BAFF-R antigen bind to the BAFF-R antigen with high affinity and high specificity, and have lower immunogenicity compared with heterologous antibodies. It has great application potential in the development of antibody drugs and cell therapy drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biotechnology, specifically relating to a fully human antibody, single-chain antibody, and antigen-binding fragment targeting the BAFF-R antigen, and particularly to a fully human antibody, single-chain antibody, and antigen-binding fragment that specifically binds to human BAFF-R antigen protein and BAFF-R antigen in its native state on the cell membrane surface. Background Technology

[0002] BAFF-R is one of the three known receptors for BAFF (B cell activating factor). It is a type III transmembrane protein receptor expressed on overactive T2 B lymphocytes and on the marginal zone and follicular mature B2 cell populations. It belongs to the TNF receptor superfamily.

[0003] BAFF-R consists of 184 amino acids, with the N-terminal extracellular region containing 78 amino acids (Met1-Leu78). While the extracellular regions of TNF receptor superfamily members typically contain 3-4 cysteine-rich domains (CRDs), BAFF-R's extracellular region contains only one CRD. Furthermore, Phe79-Val99 constitutes the transmembrane domain of BAFF-R, and Ser100-Gln184 constitutes its intracellular domain.

[0004] BAFF-R exhibits high specificity, primarily expressed in B cells, and specifically binds to BAFF, without binding to other members of the TNF family. BAFF-R mRNA is highly expressed in secondary lymphoid organs (spleen and lymph nodes), lowly expressed in peripheral blood leukocytes and the thymus, but not expressed in bone marrow or fetal liver. BAFF-R protein is expressed only in mature normal B lymphocytes and B lymphoma cells. Furthermore, it has been reported that approximately 5% of spleen CD4 in mouse lymphocytes is expressed. + T cells (80% of CD4) + CD25 + The T-reg also expresses BAFF-R.

[0005] BAFF-R is the main mediator of BAFF regulation of B cell differentiation. The BAFF / BAFF-R signaling pathway plays an important role in the proliferation of B lymphoma cells. Upregulation of BAFF-R expression is associated with the progression of B-cell lymphoma and pre-B-ALL. Mice with BAFF-R mutations or knockouts exhibit significant B-cell reduction. Furthermore, the BAFF / BAFF-R signaling pathway also plays an important role in autoimmune diseases.

[0006] Monoclonal antibodies targeting BAFF-R have been used in multiple clinical trials for autoimmune diseases, such as Novartis' VAY736 (NCT03217422, NCT03574545, NCT03656562). Genentech has also conducted research on anti-BR3 antibody therapy for autoimmune diseases. Research on its application in cancer treatment is limited. For example, it has been used to treat relapsed or refractory lymphocytic leukemia (NCT02137889). Two BAFF-R-targeted CAR-T therapies have been reported. Turazzi et al. first attempted to use BAFF-R CAR-T for B-ALL treatment, obtaining promising in vitro functional data. Hong Qin et al. from Hope City also reported that BAFF-R CAR-T can effectively eliminate CD19 knockout tumor cells in animal models.

[0007] Therefore, BAFF-R is an effective therapeutic target for many cancers, autoimmune diseases, and various other diseases characterized by BAFF-R expression. Developing fully human antibodies against BAFF-R is of great significance and application value for the research and development of BAFF-R expression-related immunotherapies. Summary of the Invention

[0008] To address the shortcomings of existing technologies, the present invention aims to provide a fully human antibody, single-chain antibody, and antigen-binding fragment targeting the BAFF-R antigen. This invention utilizes a fully human phage antibody library for antibody screening to directly obtain fully human monoclonal antibodies. Compared to humanized murine antibodies, fully human antibodies exhibit lower immunogenicity and show great potential for application in the development of antibody drugs (including monoclonal antibodies, bispecific antibodies, and ADCs) and cell therapy drugs (including CAR-T and CAR-NK). The fully human antibody, single-chain antibody, and antigen-binding fragment targeting the BAFF-R antigen provided by this invention possess high affinity and can also be applied to the development of diagnostic kits.

[0009] To achieve this objective, the present invention employs the following technical solution:

[0010] In a first aspect, the present invention provides an antigen-binding fragment targeting the BAFF-R antigen, the antigen-binding fragment comprising a light chain variable region and / or a heavy chain variable region, the light chain variable region comprising LCDR1, LCDR2 and LCDR3, and the heavy chain variable region comprising HCDR1, HCDR2 and HCDR3.

[0011] The amino acid sequence of LCDR1 is SEQ ID NO:7;

[0012] The amino acid sequence of LCDR2 is SEQ ID NO:8;

[0013] The amino acid sequence of LCDR3 is SEQ ID NO:9;

[0014] The amino acid sequence of HCDR1 is SEQ ID NO:10;

[0015] The amino acid sequence of HCDR2 is SEQ ID NO:11;

[0016] The amino acid sequence of HCDR3 is SEQ ID NO:12.

[0017] In this invention, the amino acid sequences of LCDR1, LCDR2, and LCDR3, and HCDR1, HCDR2, and HCDR3 are as follows:

[0018] The amino acid sequence of LCDR1 is SSDVGGYNY (SEQ ID NO:7);

[0019] The amino acid sequence of LCDR2 is EVS (SEQ ID NO:8);

[0020] The amino acid sequence of LCDR3 is SSYTSSSTYV (SEQ ID NO:9);

[0021] The amino acid sequence of HCDR1 is GFSLSTSGVG (SEQ ID NO:10);

[0022] The amino acid sequence of HCDR2 is IYWDDDK (SEQ ID NO:11);

[0023] The amino acid sequence of HCDR3 is ARYAGQYSGMWPWDY (SEQ ID NO:12).

[0024] Preferably, the amino acid sequence of the light chain variable region includes a sequence that has at least 90% identity with SEQ ID NO:5 (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%), and the amino acid sequence of the heavy chain variable region includes a sequence that has at least 90% identity with SEQ ID NO:6 (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%).

[0025] More preferably, the amino acid sequence of the light chain variable region is SEQ ID NO:5, and the amino acid sequence of the heavy chain variable region is SEQ ID NO:6.

[0026] In a second aspect, the present invention provides a single-chain antibody targeting the BAFF-R antigen, the single-chain antibody comprising the antigen-binding fragment targeting the BAFF-R antigen described in the first aspect.

[0027] Preferably, the amino acid sequence of the single-chain antibody targeting the BAFF-R antigen includes a sequence that has at least 90% identity with SEQ ID NO:4.

[0028] More preferably, the amino acid sequence of the single-chain antibody targeting the BAFF-R antigen is SEQ ID NO:4.

[0029] In this invention, the single-chain antibody includes a light chain variable region and / or a heavy chain variable region, wherein the light chain variable region includes LCDR1, LCDR2 and LCDR3, and the heavy chain variable region includes HCDR1, HCDR2 and HCDR3.

[0030] The amino acid sequence of LCDR1 is SEQ ID NO:7;

[0031] The amino acid sequence of LCDR2 is SEQ ID NO:8;

[0032] The amino acid sequence of LCDR3 is SEQ ID NO:9;

[0033] The amino acid sequence of HCDR1 is SEQ ID NO:10;

[0034] The amino acid sequence of HCDR2 is SEQ ID NO:11;

[0035] The amino acid sequence of HCDR3 is SEQ ID NO:12.

[0036] Thirdly, the present invention provides a fully human antibody targeting the BAFF-R antigen, wherein the fully human antibody comprises the antigen-binding fragment targeting the BAFF-R antigen described in the first aspect.

[0037] In this invention, the fully human antibody includes a light chain variable region and / or a heavy chain variable region, wherein the light chain variable region includes LCDR1, LCDR2 and LCDR3, and the heavy chain variable region includes HCDR1, HCDR2 and HCDR3.

[0038] The amino acid sequence of LCDR1 is SEQ ID NO:7;

[0039] The amino acid sequence of LCDR2 is SEQ ID NO:8;

[0040] The amino acid sequence of LCDR3 is SEQ ID NO:9;

[0041] The amino acid sequence of HCDR1 is SEQ ID NO:10;

[0042] The amino acid sequence of HCDR2 is SEQ ID NO:11;

[0043] The amino acid sequence of HCDR3 is SEQ ID NO:12.

[0044] In this invention, the fully human antibody includes variants of the CDR sequence of the light chain variable region and / or the heavy chain variable region, wherein the variant of the CDR sequence has at least 90% sequence identity with the CDR sequence of the light chain variable region and / or the heavy chain variable region (e.g., it may be 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, etc.), or contains at least one and no more than 10, or no more than 5, 4, 3, 2, or 1 amino acid change on the CDR sequence.

[0045] Preferably, the amino acid sequence of the light chain variable region is SEQ ID NO:5.

[0046] Preferably, the amino acid sequence of the heavy chain variable region is SEQ ID NO:6.

[0047] Fourthly, the present invention provides a nucleic acid molecule that encodes the antigen-binding fragment targeting the BAFF-R antigen as described in the first aspect, the single-chain antibody targeting the BAFF-R antigen as described in the second aspect, or the fully human antibody targeting the BAFF-R antigen as described in the third aspect.

[0048] In this invention, the nucleic acid molecule includes:

[0049] SEQ ID NO:1 is a nucleotide sequence encoding a single-chain antibody (ScFv);

[0050] SEQ ID NO:2 is a nucleotide sequence encoding the light chain variable region (VL);

[0051] SEQ ID NO:3 is a nucleotide sequence encoding the variable region (VH) of the heavy chain.

[0052] Fifthly, the present invention provides an expression vector comprising the nucleic acid molecule described in the fourth aspect.

[0053] Preferably, the expression vector includes a plasmid, a retroviral vector, or a lentiviral vector.

[0054] In a sixth aspect, the present invention provides a host cell containing the expression vector described in the fifth aspect, or having an exogenous nucleic acid molecule described in the fourth aspect integrated into the genome of the host cell.

[0055] In a seventh aspect, the present invention provides a pharmaceutical composition comprising any one or a combination of at least two of the antigen-binding fragment targeting the BAFF-R antigen described in the first aspect, the single-chain antibody targeting the BAFF-R antigen described in the second aspect, or the fully human antibody targeting the BAFF-R antigen described in the third aspect.

[0056] Preferably, the pharmaceutical composition further includes a pharmaceutically acceptable carrier and / or diluent.

[0057] Eighthly, the present invention provides a kit for detecting BAFF-R protein in a sample, the kit comprising any one or a combination of at least two of the antigen-binding fragment targeting BAFF-R antigen as described in the first aspect, the single-chain antibody targeting BAFF-R antigen as described in the second aspect, or the fully human antibody targeting BAFF-R antigen as described in the third aspect.

[0058] In this invention, the detection can be in vitro or in vivo.

[0059] In a ninth aspect, the present invention provides the use of any one or a combination of at least two of the antigen-binding fragment targeting the BAFF-R antigen described in the first aspect, the single-chain antibody targeting the BAFF-R antigen described in the second aspect, the fully human antibody targeting the BAFF-R antigen described in the third aspect, the host cell described in the sixth aspect, or the pharmaceutical composition described in the seventh aspect in the preparation of a medicament for preventing, alleviating, improving, or inhibiting a disease or condition.

[0060] Preferably, the disease or symptom is selected from: cancer or autoimmune diseases.

[0061] Preferably, the cancer is a B-cell malignant tumor.

[0062] In a tenth aspect, the present invention provides a method for treating a disease or symptom, the method comprising eliminating, inhibiting or reducing BAFF-R activity by administering to a patient in need any one or a combination of at least two of the following: an antigen-binding fragment targeting the BAFF-R antigen as described in the first aspect; a single-chain antibody targeting the BAFF-R antigen as described in the second aspect; a fully human antibody targeting the BAFF-R antigen as described in the third aspect; a host cell as described in the sixth aspect; or a pharmaceutical composition as described in the seventh aspect; thereby preventing, alleviating, improving or inhibiting the disease or symptom.

[0063] Preferably, the disease or symptom is selected from: cancer or autoimmune diseases.

[0064] Preferably, the cancer is a B-cell malignant tumor.

[0065] In one aspect, the present invention provides an antibody or fragment that competes with the antigen-binding fragment targeting the BAFF-R antigen described in the first aspect, the single-chain antibody targeting the BAFF-R antigen described in the second aspect, or the fully human antibody targeting the BAFF-R antigen described in the third aspect for the same epitope.

[0066] Other aspects and advantages of the invention will be readily apparent to those skilled in the art from the following detailed description. Only exemplary embodiments of the invention are shown and described in the following detailed description. As will be appreciated by those skilled in the art, the content of this invention enables them to make modifications to the disclosed specific embodiments without departing from the spirit and scope of the invention. Accordingly, the descriptions in the accompanying drawings and specification are merely exemplary and not restrictive.

[0067] The numerical range described in this invention includes not only the point values ​​listed above, but also any point values ​​within the numerical ranges not listed above. Due to space limitations and for the sake of brevity, this invention will not exhaustively list all the specific point values ​​included in the range.

[0068] Compared with the prior art, the present invention has the following beneficial effects:

[0069] (1) The fully human antibodies, single-chain antibodies and antigen-binding fragments targeting BAFF-R antigen described in this invention have high specificity, bind to BAFF-R positive cell lines, and do not bind to BAFF-R negative cell lines.

[0070] (2) The fully human antibody, single-chain antibody, and antigen-binding fragment targeting the BAFF-R antigen described in this invention bind to BAFF-R with high affinity (KD value 7.62E-10). Compared with heterologous antibodies, the fully human antibody or its single-chain antibody or fragment targeting BAFF-R has lower immunogenicity. Attached Figure Description

[0071] Figure 1 This is the general procedure for screening specific antibodies targeting BAFF-R from a phage antibody library according to the present invention.

[0072] Figure 2 The results are from an enzyme-linked immunosorbent assay (ELISA) of selected phage monoclonal antibodies against the target antigen and control antigen in Example 2.

[0073] Figure 3 The results of flow cytometry analysis (FACS) show the binding of selected phage monoclonal cells from Example 2 to K562-BAFF-R and K562 cells.

[0074] Figure 4AThe results are flow cytometry analysis of the phage monoclonal strains screened in Example 3 combined with various BAFF-R positive and negative cell lines, including the K562-BAFF-R cell line and the K562 cell line.

[0075] Figure 4B The results are flow cytometry analysis of the bacteriophage monoclonal strains screened in Example 3 combined with various BAFF-R positive and negative cell lines, including the NALM6 cell line and the Jurkat cell line.

[0076] Figure 5 The figure shows the results of enzyme-linked immunosorbent assay (ELISA) analysis of the phage monoclonal samples screened in Example 4 with BAFF-R antigen proteins and unrelated antigens from various companies. The bar charts for each test sample and control group, from left to right, represent the test results of the proteins Kactus BAFFR-his bio, ACRO-BAFFR-Fc, SB-BAFFR-Fc, Kactus-CD19-Fc, ACRO-CD70-his, and SA.

[0077] Figure 6 The figure shows the results of enzyme-linked immunosorbent assay (ELISA) analysis of the protein level of the phage monoclonal samples screened in Example 5 against the target antigen and unrelated antigens. In the figure, the bar charts corresponding to each test sample and control group represent the test results of Kactus BAFFR-his bio, Kactus-IL10-Bio-his, and SA from left to right.

[0078] Figure 7 The results of the detection of BAFF-R antigen expressed in the cell line used in Example 5 are shown in the PE anti-human BAFF-R Ab positive detection antibody test.

[0079] Figure 8 The results of flow cytometry analysis show the binding of the phage monoclonal strains screened in Example 5 to BAFF-R positive and negative cell lines at the protein level. Detailed Implementation

[0080] Unless otherwise stated, all technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art.

[0081] Antibodies are immunoglobulins secreted by plasma cells (effector B cells) and used by the body's immune system to neutralize foreign substances (peptides, viruses, bacteria, etc.). These foreign substances are correspondingly called antigens. The basic structure of an antibody molecule is a tetramer composed of two identical heavy chains and two identical light chains. Based on the conservation of amino acid sequences, the heavy and light chains are divided into a variable region (V) located at the amino terminus and a constant region (C) located at the carboxyl terminus. The interaction between the variable region of one heavy chain (HCVR, also known as VH) and the variable region of one light chain (LCVR, also known as VL) forms the antigen-binding site (Fv). Within the variable region, the composition and sequence of amino acid residues in certain areas are more variable than in other areas (backbone regions, FR), and these are called hypervariable regions (HVR). Hypervariable regions are actually the key sites for antibody-antigen binding. Because these hypervariable region sequences are complementary to the antigenic determinants, they are also called complementarity-determining regions (CDRs). Both the heavy chain and the light chain have three complementary determinant regions, referred to as HCDR1, HCDR2, HCDR3 and LCDR1, LCDR2, LCDR3, respectively.

[0082] A single-chain antibody (scFv) is composed of the variable regions of the antibody heavy chain and light chain linked together by a short peptide to form a single peptide chain. Through proper folding, the variable regions from the heavy and light chains interact non-covalently to form the Fv segment, thus allowing scFv to retain its affinity for the antigen relatively well.

[0083] "Mouse-derived antibodies" are antibodies produced by mice against specific antigens, typically referring to antibodies produced by mouse B lymphocytes. In most cases, these mouse-derived antibodies are monoclonal antibodies produced by hybridoma cells. The fully human antibody in this invention is obtained through screening a human phage antibody library, and it exhibits reduced immunogenicity compared to mouse-derived antibodies, making it more suitable for therapeutic applications in humans.

[0084] The “fully human antibody or its single-chain antibody or fragment” as described in this invention generally refers to any form of antigen-binding molecule capable of binding to a target antigen. For example, the antigen-binding molecule may be a protein or polypeptide, including, for example, antibodies and their antigen-binding fragments, single-chain scFv antibodies, single-domain antibodies, various fusions and conjugates constructed based on scFv, such as scFv-Fc antibodies, immunoconjugates, antibody-drug conjugates (ADCs), multi / bispecific antibodies, and chimeric antigen receptors (CARs).

[0085] BAFFR, or BAFF-R, is the main mediator of BAFF's regulation of B-cell differentiation. The BAFF / BAFF-R signaling pathway plays a crucial role in the proliferation of B-cell lymphoma cells. Upregulation of BAFF-R expression is associated with the progression of B-cell lymphoma and pre-B-ALL. BAFF-R exhibits high specificity, being primarily expressed in B cells and specifically binding to BAFF, without binding to other members of the TNF family. Therefore, BAFF-R is an effective therapeutic target for many cancers, autoimmune diseases, and various other diseases characterized by BAFF-R expression.

[0086] When referring to amino acid or nucleotide sequences, the term "sequence identity" (also known as "sequence uniformity") refers to the degree of similarity between two amino acid or nucleotide sequences (e.g., a query sequence and a reference sequence), typically expressed as a percentage. Generally, sequence alignment is performed and gaps (if any) are introduced before calculating the percentage of similarity between two amino acid or nucleotide sequences. If, at a certain alignment position, the amino acid residues or bases in the two sequences are the same, the two sequences are considered to be identical or matched at that position; if the amino acid residues or bases in the two sequences are different, they are considered to be inconsistent or mismatched at that position. In some algorithms, sequence identity is obtained by dividing the number of matched positions by the total number of positions in the alignment window. In other algorithms, the number of gaps and / or gap length are also taken into account. For the purposes of this invention, the publicly available alignment software BLAST (available at ncbi.nlm.nih.gov) can be used to obtain the optimal sequence alignment and calculate the sequence identity between two amino acid or nucleotide sequences using default settings. In some embodiments, the “at least 90% sequence identity” of the present invention includes, but is not limited to, at least 95%, at least 98%, at least 99%, or even 100% sequence identity.

[0087] In some embodiments, the fully human antibody provided by the present invention further includes an amino acid sequence that has at least 90% sequence identity with the sequence shown in SEQ ID NO:4 (e.g., at least 95%, at least 98%, at least 99%, or even 100% sequence identity).

[0088] Those skilled in the art will understand that, based on the specific sequences provided herein, variants of the BAFF-R-targeting antibodies provided herein can be obtained by substituting, deleting, or adding a few amino acids and verifying or screening the binding ability or biological activity of the resulting products with the corresponding antigen BAFF-R. These variants should also be included within the scope of this invention. For example, the fully human antibody of this invention or its single-chain antibody or antigen-binding fragment may have at least one and no more than 10, or no more than 5, 4, 3, 2, or 1 amino acid change in its full-length or CDR sequence.

[0089] Those skilled in the art will also understand that, based on the specific heavy chain variable region sequence provided herein, a light chain variable region that matches the heavy chain variable region and maintains BAFF-R binding ability can be obtained by using BAFF-R as an antigen to screen antibody light chain libraries (such as human phage light chain libraries). Anti-BAFF-R antibody molecules obtained in this manner are also included within the scope of this invention.

[0090] In some embodiments, the antigen-binding molecule of the present invention may further comprise post-translational modifications. Examples of post-translational protein modifications include phosphorylation, acetylation, methylation, ADP-riboylation, ubiquitination, glycosylation, carbonylation, ubiquitin-like formation, biotinylation, or the addition of a polypeptide side chain or hydrophobic group. Thus, the modified soluble polypeptide may comprise non-amino acid components, such as lipids, polysaccharides, or monosaccharides, as well as phosphates. A preferred form of glycosylation is sialylation modification, which binds one or more sialic acid groups to the polypeptide. Sialic acid groups improve protein solubility and serum half-life, while also reducing the protein's potential immunogenicity. See Raju et al. Biochemistry. 2001 31; 40(30):8868-76.

[0091] When referring to pharmaceutical compositions, the term "pharmaceuticalally acceptable carrier" refers to substances such as solid or liquid diluents, fillers, antioxidants, and stabilizers that can be safely administered to humans and / or animals without excessive adverse side effects, and which are suitable for maintaining the activity of the drug or active agent contained therein.

[0092] "Therapeutic effective amount" refers to the amount of an active compound sufficient to elicit a biological or medical response in a subject as desired by a clinician. In this invention, the "therapeutic effective amount" of the antibody can be determined by those skilled in the art based on factors such as the route of administration, the subject's weight, age, and condition. For example, a typical daily dose range can be from 0.01 mg to 100 mg of the active ingredient per kg of body weight. The administration methods of the antibody in this invention include, but are not limited to, injection, such as intravenous, intramuscular, intra-arterial, subcutaneous, or intraperitoneal administration.

[0093] An epitope is a portion of a molecule that is bound to an antigen-binding protein (e.g., an antibody). An epitope may comprise a non-adjacent portion of the molecule (e.g., in a polypeptide, amino acid residues that are not adjacent on the major sequence of the polypeptide but are close enough to each other in the trivalent and tetravalent structures of the polypeptide to be bound to an antigen-binding protein).

[0094] This invention provides a kit comprising one or more containers containing a large number of gene constructs encoding the polypeptides of this invention, and pharmaceutically acceptable excipients. The kit may also include instructions for use. The kit may also include a notification in the form prescribed by a government agency regulating the production, use, or sale of pharmaceuticals or biological products, indicating that permission has been obtained from the agency regulating the production, use, or sale of the drug for human use.

[0095] Research Overview

[0096] This invention utilizes a fully human phage antibody library for antibody screening to directly obtain fully human monoclonal antibodies. Compared to traditional hybridoma technology, it eliminates the difficult humanization step of murine antibodies, and the fully human antibodies exhibit lower immunogenicity than humanized murine antibodies, showing great potential for application in the development of antibody drugs (including monoclonal antibodies, bispecific antibodies, ADCs, etc.) and cell therapy drugs (including CAR-T, CAR-NK, etc.). Furthermore, the high-affinity specific antibodies provided by this invention can also be used in the development of diagnostic reagents.

[0097] This invention utilizes a large-capacity phage antibody library to screen for fully human BAFF-R-specific antibodies, and evaluates the specificity of these antibodies at the phage level using ELISA and FACS experiments. Ultimately, this invention yields several fully human antibody clones with good specificity.

[0098] This invention uses different antibody libraries and, through panning of recombinant BAFF-R protein, selects a total of 182 monoclonal antibodies for initial screening using enzyme-linked immunosorbent assay (ELISA) and flow cytometry (FACS). Among them, 39 clones specifically bind to the Kactus BAFF-R-his-Bio antigen and BAFF-R-expressing Kactus BAFF-R-his-Bio positive cells K562-BAFF-R, but do not bind to the control protein SA and BAFF-R-expressing negative cells K562.

[0099] Sequencing yielded five different monoclonal sequences: #1 (also known as Clone 1), #4 (also known as Clone 4), #10 (also known as Clone 10), #14 (also known as Clone 14), and #22 (also known as Clone 22). These five antibodies were then identified by flow cytometry (FACS) with various BAFF-R positive (K562-BAFF-R, NALM6) and negative (K562, Jurkat) cell lines. Enzyme-linked immunosorbent assay (ELISA) was also performed to identify BAFF-R proteins (Kactus BAFF-R-his-Bio, ACRO-BAFF-R-Fc, SB-BAFF-R-Fc) and unrelated proteins (Kactus-CD19-Fc, ACRO-CD70-his, SA) from different companies. All five clones exhibited good binding affinity and specificity on multiple cell lines and various protein antigens. Subsequently, IgG antibodies against these clones were prepared, and the binding affinity and specificity of these five antibodies to BAFF-R positive (NALM6) and negative cell lines (Jurkat) were further confirmed at the protein level. Their binding characteristics to the BAFF-R target antigen (Kactus BAFF-R-his-Bio) and unrelated proteins (human-IL10-his-Bio; SA) were also assessed. The affinity of these five clones was analyzed using Sartorius's molecular interaction technique (BLI). One clone, #10, exhibited superior affinity and showed excellent binding affinity and specificity to both the antigen and cells. The amino acid sequence of the corresponding antibody CDRs is shown below:

[0100] LCDR1 is SSDVGGYNY (SEQ ID NO:7);

[0101] LCDR2 is EVS (SEQ ID NO:8);

[0102] LCDR3 is SSYTSSSTYV (SEQ ID NO:9);

[0103] HCDR1 is GFSLSTSGVG (SEQ ID NO:10);

[0104] HCDR2 is IYWDDDK (SEQ ID NO:11);

[0105] HCDR3 is ARYAGQYSGMWWPWDY (SEQ ID NO: 12).

[0106] Obtaining this clone lays the foundation for the subsequent development of fully human BAFF-R CAR-T products or antibody drugs. The general process of this invention for screening specific antibodies targeting BAFF-R from a phage antibody library is as follows: Figure 1 As shown.

[0107] The amino acid and nucleic acid sequences involved in this invention are shown below:

[0108] SEQ ID NO:1:#10 ScFv DNA sequence

[0109] .

[0110] SEQ ID NO:2: #10 VL DNA sequence

[0111] cagtctgccctgactcagcctgcctccgtgtctgggtctcctggacagtcgatcaccatctcctgcactggaaccagcagtgacgttggtggttataactatgtctcctggtaccaacagcacccaggcaaagcccccaaactcatgatttatgaggtcagtaatcggccctcaggggtttctaatcgcttctctggctccaagtctggcaacacggcctccctgaccatctctgggctccaggctgaggacgaggctgattattactgcagctcatatacaagcagcagcacttatgtcttcggaactgggaccaaggtcaccgtcctaggt。

[0112] SEQ ID NO:3: #10 VH DNA sequence

[0113] cagatcaccttgaaggagtctggtcctacgctggtgaaacccacacagaccctcacgctgacctgcaccttctctgggttctcactcagcactagtggagtgggtgtgggctggatccgtcagcccccaggaaaggccctggagtggcttgcactcatttattgggatgatgataagcgctacagcccatctctgaagagcaggctcaccatcaccaaggacacctccaaaaaccaggtggtccttacaatgaccaacatggaccctgtggacacagccacatattactgtgcgcgctacgctggtcagtactctggtatgtggccgtgggattactggggtcaaggtactctggtgaccgtctcctca。

[0114] SEQ ID NO:4: #10 ScFv amino acid sequence

[0115] QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTYVFGTGTKVTVLGSRGGGGSGGGGSGGGGSLEQITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCARYAGQYSGMWPWDYWGQGTLVTVSS.

[0116] SEQ ID NO:5: #10 VL amino acid sequence

[0117] QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYEVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTYVFGTGTKVTVLG.

[0118] SEQ ID NO:6: #10 VH amino acid sequence

[0119] QITLKESGPTLVKPTQTLTLTCTFSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCARYAGQYSGMWPWDYWGQGTLVTVSS.

[0120] SEQ ID NO:7: #10 LCDR1 amino acid sequence

[0121] SSDVGGYNY.

[0122] SEQ ID NO:8: #10 LCDR2 amino acid sequence

[0123] EVS.

[0124] SEQ ID NO:9: #10 LCDR3 amino acid sequence

[0125] SSYTSSSTYV.

[0126] SEQ ID NO:10: #10 HCDR1 amino acid sequence

[0127] GFSLSTSGVG.

[0128] SEQ ID NO:11: #10 HCDR2 amino acid sequence

[0129] IYWDDDK.

[0130] SEQ ID NO:12: #10 HCDR3 amino acid sequence

[0131] ARYAGQYSGMWPWDY.

[0132] The present invention will be described in detail below with reference to specific embodiments.

[0133] The technical solution of the present invention will be further illustrated below through specific embodiments. Those skilled in the art should understand that the embodiments described are merely illustrative of the present invention and should not be construed as limiting the invention in any way.

[0134] Where specific techniques or conditions are not specified in the examples, they shall be performed in accordance with the techniques or conditions described in the literature in this field, or in accordance with the product instructions. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased through legitimate channels.

[0135] Example 1: Enrichment of specific antibody clones targeting the BAFF-R protein from a phage antibody library by affinity panning.

[0136] Appropriate negative and positive panning strategies were employed to enrich the desired specific antibody clones from the phage antibody library.

[0137] (1) Construction of phage antibody library:

[0138] The constructed phage antibody libraries include natural libraries, semi-synthetic libraries, and single-domain libraries. Semi-synthetic phage antibody libraries, used in conjunction with natural libraries, address the issue of the natural libraries potentially lacking high-affinity BAFF-R antibody clones. Single-domain phage antibody libraries are antibody libraries composed solely of the variable region amino acids of heavy chain antibodies, with molecular weights of only 12–15 kDa, yet possessing similar or higher specificity and affinity than traditional antibodies. Furthermore, the stable physicochemical properties, high affinity, ease of recombinant expression, and ease of combination with other target or epitope antibodies of single-domain antibodies have made them highly attractive.

[0139] (2) Protein screening:

[0140] Using the target antigen Kactus BAFF-R-his-Bio as the positive screening protein, multiple rounds of panning were performed to obtain a phage pool enriched with target antibody clones.

[0141] The experimental steps are as follows:

[0142] 1) Block the SA magnetic beads with blocking solution for 2 hours, and then bind the target antigen Kactus BAFF-R-his-Bio to the blocked SA magnetic beads.

[0143] 2) Add phage library (containing 5×10⁻⁶ cells / mL) 12 (One phage particle) and a clean SA magnetic bead are incubated together to eliminate phage antibody clones that do not specifically bind to the SA magnetic beads;

[0144] 3) After incubation, the supernatant was transferred to SA magnetic beads bound to the target antigen and incubated for a longer period to allow the phage to bind to the target antigen.

[0145] 4) Wash the magnetic beads with detergent to remove unbound phages;

[0146] 5) Elute the positive phages from the target antigen with elution buffer, and then neutralize them with neutralization solution;

[0147] 6) Reinfect the host bacteriophage XL1-blue with the eluted phage to amplify the recovered phage; retain a small amount of sample for serial dilution, infect the host bacteriophage, plate with Amp antibody plates, and calculate the number of recovered phages;

[0148] 7) Repeat steps 1) to 6), usually requiring 3 to 4 rounds of screening, until a significant increase in phage recovery rate (number of eluted phages / number of phages added) is observed.

[0149] The enriched phage pool can be used for subsequent monoclonal selection and ELISA / FACS screening.

[0150] The main materials and reagents used in this embodiment are from the following sources:

[0151] A fully human phage antibody library, including natural, semi-synthetic, and single-domain libraries;

[0152] Helper phage KO7, Thermo / Invitrogen, 18311019;

[0153] Recombinant biotinylated Human BAFF-R Protein, Kactus, BAF-HM40RB (target antigen Kactus BAFF-R-his-Bio);

[0154] BeaverBeads TM Streptavidin, Beaver Biology, 22307-10;

[0155] High binding ELSIA plate, Costar, #3590;

[0156] Blocking solution: PBS + 3% BSA;

[0157] Rinse solution: PBS + 0.1% Tween 20;

[0158] Elution buffer: 0.2M Glycine, pH 2.2

[0159] Neutralization solution: 1M Tris, pH 9.1

[0160] (3) Experimental results:

[0161] Using different antibody libraries, four rounds of protein panning were conducted, and a significant increase in recovery rate was observed in each panning. The results are shown in Table 1, which demonstrates that the antibody clones were effectively enriched.

[0162] Table 1

[0163]

[0164] As can be seen, after four rounds of screening, different antibody libraries were enriched (the recovery rate in the fourth round was significantly higher than that in the previous round).

[0165] Example 2 uses enzyme-linked immunosorbent assay (ELISA) and flow cytometry (FACS) to screen specific clones from an enriched phage pool.

[0166] (1) Purpose and principle:

[0167] The phage pool enriched through affinity panning contains phage antibodies of various properties, including specific clones, non-specific clones, and negative clones. To obtain specific clones, single clones are isolated and packaged into monoclonal phages. A large number of monoclonal clones are then screened using enzyme-linked immunosorbent assay (ELISA) and flow cytometry (FACS) to select those that specifically bind to both the BAFF-R protein and the BAFF-R-positive cell line K562-BAFF-R. These specific monoclonal clones are further analyzed using DNA sequencing to determine the unique antibody sequence they contain.

[0168] In ELISA screening, the binding of streptavidin to biotin makes the biotinylated target antigen Kactus BAFF-R-his-Bio more closely resemble its native antigen conformation in the reaction solution. Cells that bind only to the target antigen Kactus BAFF-R-his-Bio without binding to the control protein (Streptavidin, SA) are identified as specific clones. FACS screening uses the BAFF-R-positive cell line K562-BAFF-R and the BAFF-R-negative cell line K562. Cells that bind only to K562-BAFF-R and not to K562 are identified as specific clones.

[0169] Candidate antibodies that can both bind to recombinantly expressed BAFF-R protein and recognize native BAFF-R molecules on the cell surface can be obtained through two primary screening methods: ELISA and FACS, for further screening.

[0170] (2) The steps of the ELISA experiment are as follows:

[0171] 1) Culture and package monoclonal phages using deep-well 96-well plates;

[0172] 2) Dilute Strepavidin to 2 μg / mL with PBS and add 100 μL / well to a high-binding microplate. Incubate at room temperature for 2 hours.

[0173] 3) Discard the coating solution, add 250 μL of blocking solution to each well, and seal overnight at 4°C;

[0174] 4) Wash the plate twice with 250μL of rinsing solution;

[0175] 5) Dilute the biotin-tagged target protein and control protein to 2 μg / mL with PBS, add 100 μg / well to a pre-coated Strepavidin microplate, and bind at room temperature for 1 h.

[0176] 6) Wash the plate twice with 250μL of rinsing solution;

[0177] 7) Add 100 μL of the phage supernatant cultured in step 1) to the well coated with the target antigen, and allow it to bind at room temperature for 2 hours;

[0178] 8) Wash the plate 4 times with 250μL of rinsing solution;

[0179] 9) Add 100 μL of mouse anti M13 primary antibody diluted 1:2000 to each well and incubate at room temperature for 45 min;

[0180] 10) Wash the plate 4 times with 250μL of rinsing solution;

[0181] 11) Add 100 μL of HRP Goat anti-mouse IgG (minimal x-reactivity) Antibody diluted 1:2000 to each well and incubate at room temperature for 45 min;

[0182] 12) Wash the plate 6 times with 250μL of rinsing solution;

[0183] 13) Add 100 μL of TMB substrate and develop for 5 to 10 minutes;

[0184] 14) Add 100 μL of 2M H2SO4 to stop the reaction and read the results on a microplate reader.

[0185] (3) The FACS initial screening test steps are as follows:

[0186] 1) Culture and package monoclonal phages using deep-well 96-well plates;

[0187] 2) Raji and Jurkat cells were washed twice with PBS and resuspended in PBS to a concentration of 1×10⁻⁶ cells. 7 / mL concentration, dispensed into 50μL portions into 96-well deep-well plates;

[0188] 3) Add 50 μL of packaged monoclonal phage to each well, mix well, and incubate at 4°C for 2 h;

[0189] 4) Wash twice with 200 μL PBS;

[0190] 5) Add 100 μL of mouse anti M13 primary antibody diluted 1:2000 per well, mix well by pipetting, and incubate at room temperature for 45 min.

[0191] 6) Wash twice with 200 μL PBS;

[0192] 7) Add 100 μL of FITC horse anti-mouse-IgG (H+L) diluted 1:300 to each well, mix well by pipetting, and incubate at room temperature for 45 min.

[0193] 8) Wash twice with 200 μL PBS; finally, resuspend the cells in 200 μL PBS;

[0194] 9) Detect the fluorescence intensity of the FITC channel of the sample using a flow cytometer and analyze the results.

[0195] The main materials and reagents used in this embodiment are as follows:

[0196] Helper phage KO7, Thermo / Invitrogen, 18311019;

[0197] Streptavidin, Pierce, 21125;

[0198] Recombinant biotinylated Human BAFF-R Protein, Kactus, BAF-HM40RB;

[0199] High binding ELSIA plate, Costar, #3590;

[0200] Corning 96Well Clear Round Bottom TC-Treated Microplate, Costar, #3799;

[0201] Blocking solution: PBS + 3% BSA;

[0202] Rinse solution: PBS + 0.1% Tween 20;

[0203] Soluble single-component TMB substrate solution, Tiangen, PA-107-02;

[0204] Anti-M13 Bacteriophage Coat Protein g8p antibody (referred to as mouse anti M13), abcam, ab9225;

[0205] HRP Goat anti-mouse IgG (minimal x-reactivity) Antibody, Biolegend, 405306;

[0206] FITC horse anti mouse-IgG(H+L), Vector, FI2000.

[0207] (4) Experimental results:

[0208] Single clones were randomly selected from the enriched phage antibody pool, packaged into phages, and then the binding of the single phages to the Kactus BAFF-R-his-Bio protein (target antigen) and the control protein SA (control protein) was detected by phage ELISA to identify BAFF-R-specific phage antibody clones. The results of enzyme-linked immunosorbent assay (ELISA) of a portion of the panned phage single clones with the target antigen and control antigen are shown below. Figure 2As shown in the figure, clones H1–H2 and H4–H7 bind well to the target antigen BAFF-R (BAFF-R-Bio-his) and do not bind to the control antigen SA, indicating good specificity. Clone H3 does not bind to either the target antigen Kactus BAFF-R-his-Bio or the control protein SA, making it a negative clone.

[0209] Flow cytometry analysis results of selected phage monoclonal antibodies binding to K562-BAFF-R and K562 cells are as follows: Figure 3 As shown in the figure. Among them, the negative control phage antibody clones are negative control clones. Clones H1-H2 and H4-H7 do not bind to K562, but bind to K562-BAFF-R cells, and are specific clones; clone H3 does not bind to either K562-BAFF-R or K562, and is a negative clone.

[0210] A total of 39 specific clones were obtained through ELISA detection and FACS initial screening.

[0211] Example 3 uses multiple cell lines to identify monoclonal specificity via FACS

[0212] (1) Experimental objective and principle:

[0213] Antibodies used for treatment must possess excellent target specificity, binding only to the target antigen and excluding any irrelevant antigens. Furthermore, the amino acid sequences of the same antigen may differ across different cell lines (isomers or mutants) or the ligands they bind may vary, necessitating an examination of whether the resulting antibodies can bind to cells positive for various target proteins. To further analyze the specificity and universality of these monoclonal antibodies and identify the best candidate clones, this embodiment uses flow cytometry to further evaluate the specificity of the initial screening clones. In this experiment, multiple BAFF-R positive and multiple BAFF-R negative cell lines were reacted with these monoclonal phage antibodies to analyze whether these clones could bind to BAFF-R antigens on different cell lines and whether they exhibited any non-specific binding to other cell lines that do not express BAFF-R. This experiment yielded several clones with excellent specificity.

[0214] (2) Experimental method: Refer to the experimental steps of FACS initial screening;

[0215] The main samples and reagents used in this embodiment are shown below:

[0216] K562-BAFF-R cell line, BAFF-R positive cell line; (IASO, homemade)

[0217] K562 cell line, BAFF-R negative cell line; (IASO, in-house)

[0218] NALM6 cell line, BAFF-R positive cell line; (IASO, in-house)

[0219] Jurkat cell line, BAFF-R negative cell line; (IASO, in-house)

[0220] The remaining reagents are the same as those used for the FACS initial screening.

[0221] (3) Experimental results:

[0222] Antibodies used for treatment must possess very high target specificity. To further analyze the specificity of these monoclonal antibodies, the unique clone obtained in Example 2 was identified using enzyme-linked immunosorbent assay (ELISA) and flow cytometry on a wider range of antigens and cell lines. The results are as follows: Figure 4A and Figure 4B As shown, Figure 4A and Figure 4B The flow cytometry results (peak shape) show the binding of selected phage monoclonals to various BAFF-R positive and negative cell lines, including the K562-BAFF-R cell line, the K562 cell line, the NALM6 cell line, and the Jurkat cell line. The negative control phage antibody clone represents the negative control. Clone 10 and Clone 22 bound to both BAFF-R positive cell lines, while Clone 1, Clone 4, and Clone 14 bound only to the BAFF-R overexpressing cell line K562-BAFF-R and not to NALM6. They did not bind to any BAFF-R negative cell lines, demonstrating good specificity.

[0223] Example 4: Identification of monoclonal specificity using antigens from different companies via ELISA

[0224] (1) Experimental objective and principle:

[0225] Antibodies used for treatment must possess excellent target specificity, binding only to the target antigen and excluding any unrelated antigens. Furthermore, the amino acid sequences of the same antigen produced by different companies may differ (isomers or mutants), necessitating an examination of whether the resulting antibodies can bind to various target proteins. To further analyze the specificity and universality of these monoclonal antibodies and identify the best candidate clones, this embodiment uses enzyme-linked immunosorbent assay (ELISA) to further evaluate the specificity of the initial screening clones. In this experiment, BAFF-R antigens purchased from different companies and various BAFF-R unrelated antigens were reacted with these monoclonal phage antibodies to analyze whether these clones could bind to different BAFF-R antigens and whether they exhibited any non-specific binding to other BAFF-R unrelated antigens. Through this experiment, several clones with excellent specificity were obtained.

[0226] (2) Experimental methods:

[0227] Refer to the experimental procedures for ELISA initial screening;

[0228] (3) The main samples and reagents used in this embodiment are as follows:

[0229] Acro-human BAFF-R Protein, his tag (referred to as ACRO-BAFF-R-Fc), ACRObiosystem, BAFFR-H52H5;

[0230] Biotinylated Human CD27 Ligand,HIS,Avitag (referred to as ACRO-CD70-his), ACRObiosystem, CDL-H82Q9;

[0231] Recombinant biotinylated Human BAFF-R Protein (Kactus BAFF-R-his-Bio for short), Kactus, BAF-HM40RB;

[0232] SB-human BAFF-R Protein, his tag, Bio (abbreviated as SB-BAFF-R-Fc), SinoBiological, 11027-H27H-B;

[0233] Recombinant biotinylated Human CD19 Protein (Kactus-CD19-Fc for short), Kactus, CD2-HE121;

[0234] Streptavidin (SA), Pierce, 21125;

[0235] PE / Dazzle TM 594 anti-human CD268 (BAFF-R) Antibody (referred to as PE anti-humanBAFF-R Ab), Biolegend, 316922.

[0236] The remaining reagents are the same as those used for the initial ELISA screening.

[0237] (4) Experimental results:

[0238] Antibodies used for treatment must have very high target specificity. To further analyze the specificity of these monoclonal antibodies, multiple clones obtained in Example 2 were identified using enzyme-linked immunosorbent assay (ELISA) on various antigens.

[0239] The results are as follows Figure 5 As shown, Figure 5 The results of enzyme-linked immunosorbent assay (ELISA) analysis of the screened phage monoclonal antibodies against BAFF-R antigen proteins and unrelated antigens from various companies are presented. Negative control refers to the negative control phage antibody clone; anti-M13 phage mouse Ab / anti-mouse HRP Ab is a negative control without phage, containing only the first antibody (Anti-M13 phage mouse Ab) and the second antibody (anti-mouse HRP Ab); anti-mouse HRP Ab is a negative control containing only the second antibody (anti-mouse HRP Ab); PE anti-human BAFF-R Ab / anti-mouse HRP Ab is a positive control with BAFF-R detection antibody added; and anti-human IgG HRP / anti-hisHRP is a positive control for detecting antigen-tagged antibodies. Figure 5 In the bar chart, the bar graphs for each test sample and control group, from left to right, represent the test results for the proteins Kactus BAFFR-his bio, ACRO-BAFFR-Fc, SB-BAFFR-Fc, Kactus-CD19-Fc, ACRO-CD70-his, and SA. Clones #4, #10, #14, and #22 bound to all three BAFF-R antigens, while clone #1 bound to two BAFF-R antigens but not to the unrelated antigens Kactus-CD19-Fc, ACRO-CD70-his, and SA. This indicates that these five clones can bind to BAFF-R antigens of different conformations with good specificity.

[0240] Example 5 further determined the binding specificity of monoclonal antibodies at the protein level using ELISA and FACS.

[0241] (1) Experimental objective and principle:

[0242] Clones specifically targeting the BAFF-R antigen were enriched from a phage antibody library through affinity panning, and after screening and identification, clones capable of binding to the BAFF-R antigen were obtained. However, the binding ability and specificity of the antibody molecules expressed in the prokaryotic system after conversion to IgG antibody molecules expressed in the eukaryotic system needed further confirmation. Therefore, we prepared IgG expression plasmids for these clones, expressed them by transient transfection into CHOS cells, and purified them into antibodies using Protein A. Then, the binding specificity of the single clones was further determined by ELISA and FACS.

[0243] (2) At the protein level, the binding specificity of monoclonal antibodies at the antibody level was further determined by ELISA:

[0244] Refer to the ELISA procedure for phage levels in Example 2.

[0245] The main samples and reagents used in this embodiment are shown below:

[0246] Same reagents as phage level ELISA;

[0247] human-IL10-his-Bio, Kactus, IL1-HM410B.

[0248] (3) Experimental results:

[0249] To further analyze whether these monoclonal antibodies retain their original binding ability and specificity after being expressed as IgG antibodies in a eukaryotic system, this example uses enzyme-linked immunosorbent assay (ELISA) to identify the five clones obtained in Example 3 as antibodies purified from Protein A to IgG form via CHOS expression on various antigens. The results are as follows: Figure 6 As shown, Figure 6 This section presents the results of enzyme-linked immunosorbent assay (ELISA) analysis of the protein levels of the selected phage monoclonal antibodies against the target antigen and unrelated antigens. PE anti-human BAFF-R Ab is a positive antibody control for the target antigen (BAFF-R), binding to the target antigen but not to the control antigen. Anti-human IgG HRP Ab is a negative antibody control with only secondary antibody added. Anti-hisHRP Ab is a positive antibody control for detecting the antigen tag, binding to the his-tagged antigen, indicating that the coated antigen has bound to the plate. Figure 6In the graph, the bar charts for each test sample and control group, from left to right, represent the test results for KactusBAFFR-his bio, Kactus-IL10-Bio-his, and SA, respectively. Clone 1, Clone 4, Clone 10, Clone 14, and Clone 22 all bound to the BAFF-R antigen but not to the two unrelated antigens, indicating that Clone 1, Clone 4, Clone 10, Clone 14, and Clone 22 can bind to the BAFF-R antigen with good specificity.

[0250] (4) Further determine the binding specificity of monoclonal antibodies at the protein level using FACS, referring to the FACS initial screening steps in Example 2.

[0251] The main samples and reagents used in this embodiment are shown below:

[0252] PE / Dazzle TM 594 anti-human CD268(BAFF-R)Antibody, Biolegend, 316922;

[0253] Fluorescein(FITC)AffiniPure Goat Anti-Human IgG, Fcγfragmentspecific, Jackson ImmunoReseach, 109-095-190.

[0254] Kactus-IL10-Bio-his,Kactus,IL1-HM410B.

[0255] (5) Experimental results:

[0256] To further analyze whether these monoclonal antibodies retain their original binding ability and specificity after being expressed as IgG antibodies in eukaryotic systems, this example used five clones obtained in Example 3 to express antibodies in CHOS and purify them into IgG antibodies using Protein A. These antibodies were then identified using enzyme-linked immunosorbent assay (ELISA) and flow cytometry on a wider range of antigens and cell lines. The results showed... Figures 7-8 middle, Figure 7 To detect the results of the assay using the positive control antibody PE anti-human BAFF-R Ab positive detection antibody against the cell line expressing BAFF-R antigen, Figure 7 This indicates that NALM6 cells are BAFF-R positive and jurakat cells are BAFF-R negative. Figure 8Flow cytometry analysis results (peak shape) of the protein binding of the selected phage monoclonals to BAFF-R positive and negative cell lines. Figure 8 The results showed that Clone 1, Clone 4, Clone 10, Clone 14, and Clone 22 all bound to the BAFF-R positive cell line NALM6, but not to the BAFF-R negative cell line Jurkat, demonstrating good specificity. Clone 10 showed the strongest binding ability to NALM6 cells. FITC anti-human IgG Ab, a negative control with only secondary antibody, did not bind to either cell line.

[0257] Example 6: Determination of Affinity to Anti-BAFF-R mAbs

[0258] (1) Experimental objective and principle:

[0259] The affinity between BAFF-R mAb and the antigen can significantly influence the cytotoxic effects and duration of CAR-T or antibody drugs in patients. To determine this important property, this embodiment employed Sartorius's Biomolecular Interaction (BLI) technology for measurement. This system utilizes biomembrane interference technology, a label-free technique that provides high-throughput biomolecular interaction information in real time. The instrument emits white light onto the sensor surface and collects the reflected light. The reflected spectrum at different frequencies is affected by the thickness of the biosensor's optical film layer; some frequencies of reflected light form constructive interference (blue), while others experience destructive interference (red). These interferences are detected by the spectrometer, forming an interference spectrum, which is displayed as the phase shift intensity (nm). Therefore, any increase or decrease in the number of molecules bound to the sensor surface will be detected in real time by the spectrometer, and this shift directly reflects the thickness of the biomembrane on the sensor surface. This allows for the acquisition of high-quality data on biomolecular interactions, enabling the determination of biomolecular interaction kinetic parameters (Kon, Kdis, and KD), providing crucial information for the research and development process.

[0260] (2) The experimental steps are as follows:

[0261] 1) Anti-BAFF-R IgG (composed by fusing the ScFv sequence of BAFF-R with human IgG4 Fc) was diluted to 10 μg / mL with loading buffer (1×PBS, pH 7.4, 0.01% BSA and 0.02% Tween 20) and loaded onto the biosensor.

[0262] 2) After the 60s equilibrium phase, the binding kinetics of BAFF-R antigen (Kactus, BAF-HM40RB) were monitored at various antigen concentrations (100 to 6.25 nM). Binding was performed for 30s and dissociation for 300s at each concentration.

[0263] 3) Regenerate the chip by washing it three times with 10mM Glycine-HCl at pH 1.5.

[0264] 4) The binding constant was analyzed using a 1:1 binding site model (BLI analysis software V11.0).

[0265] (3) Experimental results:

[0266] Affinity refers to the strength of binding between a single molecule and its ligand, and is usually measured and reported using the equilibrium dissociation constant (KD). The equilibrium dissociation constant can be used to assess and rank the strength of the interaction between two molecules. The binding of an antibody to its antigen is a reversible process, and the rate of binding is proportional to the concentration of the reactant. The smaller the KD value, the greater the affinity of the antibody for its target. The affinity test results are shown in Table 2 (Affinity test results of anti-BAFF-R IgG): Clone 1 IgG, Clone 4 IgG, Clone 10 IgG, Clone 14 IgG, and Clone 22 IgG can all bind to the BAFF-R antigen, and Clone 10 IgG has a slightly higher affinity than the other clones.

[0267] Table 2

[0268] Analytes KD(M) kon(1 / Ms) kdis(1 / s) Clone 1 IgG 3.35E-09 3.54E+05 1.19E-03 Clone 4 IgG 2.27E-09 4.25E+05 9.66E-04 Clone 10 IgG 7.62E-10 1.14E+05 8.72E-05 Clone 14 IgG 3.30E-09 1.86E+05 6.14E-04 Clone 22 IgG 6.42E-09 4.81E+05 3.09E-03

[0269] In summary, the fully human antibodies, single-chain antibodies, or antigen-binding fragments targeting the BAFF-R antigen described in this invention exhibit high specificity, binding to BAFF-R-positive cell lines but not to BAFF-R-negative cell lines. These antibodies bind to BAFF-R antigen with high affinity and specificity, and compared to heterologous antibodies, they possess lower immunogenicity, demonstrating significant potential for application in antibody and cell therapy drug development.

[0270] The applicant declares that the above description is only a specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily conceived by those skilled in the art within the technical scope disclosed in the present invention fall within the protection and disclosure scope of the present invention.

Claims

1. An antigen-binding fragment targeting the BAFF-R antigen, characterized in that, The antigen-binding fragment includes a light chain variable region and a heavy chain variable region. The light chain variable region includes LCDR1, LCDR2 and LCDR3, and the heavy chain variable region includes HCDR1, HCDR2 and HCDR3. The amino acid sequence of LCDR1 is SEQ ID NO:7; The amino acid sequence of LCDR2 is SEQ ID NO:8; The amino acid sequence of LCDR3 is SEQ ID NO:9; The amino acid sequence of HCDR1 is SEQ ID NO:10; The amino acid sequence of HCDR2 is SEQ ID NO:11; The amino acid sequence of HCDR3 is SEQ ID NO:

12.

2. The antigen-binding fragment targeting the BAFF-R antigen according to claim 1, characterized in that, The amino acid sequence of the light chain variable region includes a sequence that is at least 90% identical to SEQ ID NO:5, and the amino acid sequence of the heavy chain variable region includes a sequence that is at least 90% identical to SEQ ID NO:

6.

3. The antigen-binding fragment targeting the BAFF-R antigen according to claim 1, characterized in that, The amino acid sequence of the light chain variable region is SEQ ID NO:5, and the amino acid sequence of the heavy chain variable region is SEQ ID NO:

6.

4. A single-chain antibody targeting the BAFF-R antigen, characterized in that, The single-chain antibody comprises the light chain variable region and the heavy chain variable region in the antigen-binding fragment targeting the BAFF-R antigen as described in any one of claims 1-3; The amino acid sequence of the single-chain antibody targeting the BAFF-R antigen includes a sequence that is at least 90% identical to SEQ ID NO:

4.

5. The single-chain antibody targeting the BAFF-R antigen according to claim 4, characterized in that, The amino acid sequence of the single-chain antibody targeting the BAFF-R antigen is SEQ ID NO:

4.

6. A fully human antibody targeting the BAFF-R antigen, characterized in that, The fully human antibody comprises the antigen-binding fragment targeting the BAFF-R antigen as described in any one of claims 1-3.

7. A nucleic acid molecule, characterized in that, The nucleic acid molecule encodes the antigen-binding fragment targeting the BAFF-R antigen as described in any one of claims 1-3, the single-chain antibody targeting the BAFF-R antigen as described in claim 4 or 5, or the fully human antibody targeting the BAFF-R antigen as described in claim 6.

8. An expression carrier, characterized in that, The expression vector comprises the nucleic acid molecule of claim 7; The expression vector includes plasmids or retroviral vectors.

9. The expression vector according to claim 8, characterized in that, The retroviral vector includes a lentiviral vector.

10. A host cell, characterized in that, The host cell contains the expression vector of claim 8 or 9, or the host cell has an exogenous nucleic acid molecule of claim 7 integrated into its genome.

11. A pharmaceutical composition, characterized in that, The pharmaceutical composition comprises any one or a combination of at least two of the antigen-binding fragment targeting the BAFF-R antigen according to any one of claims 1-3, the single-chain antibody targeting the BAFF-R antigen according to claim 4 or 5, or the fully human antibody targeting the BAFF-R antigen according to claim 6. The pharmaceutical composition also includes a pharmaceutically acceptable carrier and / or diluent.

12. A kit for detecting BAFF-R protein in a sample, characterized in that, The kit comprises any one or a combination of at least two of the antigen-binding fragment targeting the BAFF-R antigen as described in any one of claims 1-3, the single-chain antibody targeting the BAFF-R antigen as described in claim 4 or 5, or the fully human antibody targeting the BAFF-R antigen as described in claim 6.

Citation Information

Patent Citations

  • BAFF-r targeted chimeric antigen receptor-modified t-cells and uses thereof

    CN109311991A

  • Anti-Baff Receptor Antibodies and Uses Thereof

    US20210261676A1